Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study - ScienceDirect

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study - ScienceDirect

Comments

Popular posts from this blog

Extraperitoneal robot assisted laparoscopic prostatectomy with Versius system: single centre experience | Prostate Cancer and Prostatic Diseases

Ivermectin, a potential anticancer drug derived from an antiparasitic drug - ScienceDirect